PubMed Health⌕ Search

Biomedical subjects

J Rogan

Publications and source records attributed to J Rogan.

10 recordsLinked to original sources
PubMed2004

Modeling traffic through a sequence of traffic lights.

We introduce a microscopic traffic model, based on kinematic behavior, which consists of a single vehicle traveling through a sequence of traffic lights that turn on and off with a specific frequency. The reconstructed function that maps the state of the vehicle from light to light displays complex behavior for certain conditions. This chaotic behavior, which arises by the discontinuous nature of the map, displays an essential ingredient in traffic patterns and could be of relevance in studying traffic situations.

Journal Article↗
PubMed1997

EVA: a new theoretically based molecular descriptor for use in QSAR/QSPR analysis.

A new descriptor of molecular structure, EVA, for use in the derivation of robustly predictive QSAR relationships is described. It is based on theoretically derived normal coordinate frequencies, and has been used extensively and successfully in proprietary chemical discovery programmes within Shell Research. As a result of informal dissemination of the methodology, it is now being used successfully in related areas such as pharmaceutical drug discovery. Much of the experimental data used in development remain proprietary, and are not available for publication. This paper describes the method and illustrates its application to the calculation of nonproprietary data, log P(ow), in both explanatory and predictive modes. It will be followed by other publications illustrating its application to a range of data derived from biological systems.

Drug Design↗
PubMed1976

Ethics and nurses.

Explore the source record for details and available documents.

Abortion, Induced↗
PubMed1972

What is authority?

Explore the source record for details and available documents.

Authoritarianism↗
PubMedDate not supplied

Indobufen in secondary prevention of transient ischaemic attack. Multicentre Ischaemic Attack Study Group.

The secondary prevention of transient ischaemic attacks was assessed in 270 patients treated orally with 100 mg indobufen given twice daily for 12 months. After 1 month's treatment, the average number and average incidence of transient ischaemic attacks were reduced significantly (P less than 0.001) and remained suppressed throughout the treatment period. Treatment was interrupted in 17 patients: in two because of side-effects (gastric disturbances); in 10 because of fatal events (six completed strokes, two myocardial infarcts and two unrelated deaths); and in five due to poor protocol compliance. Progression to reversible ischaemic neurological deficit occurred in five patients. Most side-effects were mild and transient, mainly occurring in the first month of treatment. Overall, indobufen was judged to have good efficacy and safety by both patients and physicians.

Cerebrovascular Disorders↗